Table 2. Clinical and MRI data evaluated of peripheral lesions.
| Clinical and MRI data | Non-clinically significant cancer (n=44) | Clinically significant cancer (n=10) | P values |
|---|---|---|---|
| Age (years), mean [SD] | 67 [9] | 76 [8] | 0.013a |
| tPSA (ng/mL), median (IQR) | 8.39 (5.52–13.89) | 14.28 (7.89–20.27) | 0.111a |
| fPSA (ng/mL), median (IQR) | 0.91 (0.53–1.92) | 1.00 (0.78–2.42) | 0.703a |
| f/tPSA, median (IQR) | 0.12 (0.93–1.88) | 0.09 (0.05–0.14) | 0.182a |
| PSAD (ng/mL2), median (IQR) | 0.19 (0.11–0.36) | 0.31 (0.19–1.06) | 0.012a |
| PV (mL), median (IQR) | 39.01 (29.78–69.45) | 36.66 (24.94–46.58) | 0.122a |
| Lesion diameter (mm), mean (SD) | 17.57 (3.61) | 19.43 (2.94) | 0.134a |
| Lesion location, n (%) | 0.817b | ||
| Base | 9 (20.5) | 3 (30.0) | |
| Middle | 14 (31.8) | 3 (30.0) | |
| Apex | 21 (47.1) | 4 (40.0) |
a, univariate cox regression analysis; b, chi-square test. MRI, magnetic resonance imaging; SD, standard deviation; IQR, interquartile range; tPSA, total prostate-specific antigen; fPSA, free PSA; f/tPSA, ratio of free-to-total PSA; PSAD, PSA density; PV, prostate volume.